The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines
The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines
复制标题
DOI：
10.1007/s10549-007-9803-5
复制
发表时间：
2008-02-01
影响因子：
3.8
通讯作者：
Reardon, Greg
中科院分区：
文献类型：
--
作者：
Dranitsaris, George;Rayson, Daniel;Reardon, Greg
背景：蒽环类药物的心脏毒性可导致停药、住院或充血性心力衰竭(CHF)。由于这种风险可能因患者而异，我们开发并测试了一种风险预测工具，用于预测接受阿霉素化疗的转移性乳腺癌(MBC)患者的心脏毒性，无论是传统的DOX配方还是聚乙二醇化脂质体(PLD)配方。方法509例MBC患者随机分为DOX(每3周60 mg/m(2))或PLD(50 mg/m(2)每4周)(O‘Brien Ann Oncol15,440-449,2004)。为每个治疗周期确定患者、疾病和治疗因素。P值为的因子
Background Cardiac toxicity from anthracyclines (ACH) can lead to therapy discontinuation, hospitalization or congestive heart failure (CHF). Since such risk may vary by patient, we developed and tested a risk-prediction tool for cardiac toxicity in metastatic breast cancer (MBC) patients receiving chemotherapy with doxorubicin, either in its traditional (DOX) or pegylated liposomal (PLD) formulation. Methods Data was obtained (n = 509) from a randomized clinical trial of MBC patients assigned either DOX (60 mg/m(2) every 3 weeks) or PLD (50 mg/m(2) every 4 weeks) (O'Brien Ann Oncol 15, 440-449, 2004). Patient, disease and treatment factors were identified for each cycle of therapy. Factors with a P-value of